ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

NicOx Taps Archimica For API Supply

March 24, 2008 | APPEARED IN VOLUME 86, ISSUE 12

French biotech company NicOx has signed an agreement with the fine chemicals maker Archimica for commercial production of the active pharmaceutical ingredient (API) naproxcinod. Naproxcinod is NicOx' lead product and the first compound in the COX-inhibiting nitric oxide-donating (CINOD) class of anti-inflammatory agents. NicOx expects to file a New Drug Application with FDA by mid-2009. Under the agreement, Archimica will supply the API from its site in Springfield, Mo.; commercial deliveries are expected by fourth-quarter 2009.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment